cetuximab,panitumumab
amgen,eli lilly
[]
proud to present at #gi23 costs of adverse event management associated with #first_line cetuximab or panitumumab in patients with metastatic #colorectal #cancer in spain just a model to remind us that patients &amp;healthsystem pay not only for treatments but also its side effects 
Especialista en Oncoloxia Médica do Servicio Galego de Saúde (SERGAS) // Medical Oncologist of Galician Public Health System MD PhD